LAVAL, QC, and CAMBRIDGE, England, March 13, 2023 /PRNewswire/ -- Liminal
BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the
"Company"), today announced that it plans to report its fourth
quarter and year ended 2022 financial results after market close on
Wednesday March 15, 2023. Liminal
will host a conference call and webcast to discuss financial
results at 8:30 am (ET) on Thursday
March 16, 2023.
To join the conference call without operator assistance, you may
register and enter your phone number at https://bit.ly/3FeNJBk to
receive an instant automated call back. You can also dial direct to
be entered to the call by an Operator by dialing 416-764-8609 and
888-390-0605, using the following passcode: 77593817. An audio
replay of the call will be available as of Thursday March 16, 2023 at 11:30 am (ET). The numbers to access the audio
replay are 416-764-8677 and 1-888-390-0541 using the following
password (593817 #). A live audio webcast of the conference call
will be available by clicking here.
About Liminal BioSciences Inc.
Liminal BioSciences is a development-stage biopharmaceutical
company focused on discovering and developing distinctive novel
small molecule therapeutics for inflammatory, fibrotic, and
metabolic diseases using our drug discovery platform with a
data-driven approach. The Company's lead program is LMNL6511, a
selective antagonist for the GPR84 receptor, and the Company is
also developing potential OXER1 antagonists. In addition to these
programs, the Company continues to explore other development
opportunities to add to its pipeline.
Liminal BioSciences has active business operations in
Canada and the United Kingdom.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Some of the forward-looking statements can be identified
by the use of forward-looking words. Statements that are not
historical in nature, including the words "anticipate," "expect,"
"suggest," "plan," "believe," "intend," "estimate," "target,"
"project," "should," "could," "would," "may," "will," "forecast"
and other similar expressions are intended to identify
forward-looking statements. These statements include those related
to Liminal BioSciences' objectives, strategies and businesses that
involve risks and uncertainties. Forward–looking information
includes statements concerning, among other things: advancement of
Liminal Biosciences' product candidates, including the timing of
the potential development of the Company's R&D programs; the
timing of initiation or nature of preclinical and clinical trials
and potential therapeutic areas. These statements are
"forward-looking" because they are based on our current
expectations about the markets we operate in and on various
estimates and assumptions. Actual events or results may differ
materially from those anticipated in these forward-looking
statements if known or unknown risks affect our business, or if our
estimates or assumptions turn out to be inaccurate. Among the
factors that could cause actual results to differ materially from
those described or projected herein include, but are not limited
to, risks associated with: the Company's ability to develop,
manufacture, and successfully commercialize product candidates, if
ever; the impact of the COVID-19 pandemic on the Company's
workforce, business operations, clinical development, regulatory
activities and financial and other corporate impacts; the
availability of funds and resources to pursue R&D projects,
clinical development, manufacturing operations or commercialization
activities; the successful and timely initiation or completion of
preclinical and clinical trials; the ability to take advantage of
financing opportunities or business opportunities in the
pharmaceutical industry. You will find a more detailed assessment
of these risks, uncertainties and other risks that could cause
actual events or results to materially differ from our current
expectations in the filings and reports the Company makes with the
U.S. Securities and Exchange Commission and Canadian Securities
Administrators, including in the Annual Report on Form 20-F for the
year ended December 31, 2021, as well
as other filings and reports Liminal Biosciences' may make from
time to time. Such risks may be amplified by the ongoing COVID-19
pandemic and any related impacts on Liminal BioSciences' business
and the global economy. As a result, we cannot guarantee that any
given forward-looking statement will materialize. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements and estimates, which speak only as
of the date hereof. We assume no obligation to update any
forward-looking statement contained in this press release even if
new information becomes available, as a result of future events or
for any other reason, unless required by applicable securities laws
and regulations.
Corporate Contact: Shrinal
Inamdar, Associate Director, Investor Relations and
Communications, s.inamdar@liminalbiosciences.com, +1
450.781.0115; Media Contact, Kaitlin
Gallagher, kgallagher@berrypr.com, +1 212.253.8881
View original
content:https://www.prnewswire.co.uk/news-releases/liminal-biosciences-to-report-fourth-quarter-and-year-ended-2022-financial-results-on-march-15-2023-301770641.html